- The approval is based on P-III IMbrave150 study involves assessing of Tecentriq (1200mg) + Avastin (15 mg/kg) on day 1 of each 21-day cycle vs sorafenib (400mg, bid) on days 1-21 of each 21-day cycle in 501 patients in a ratio (2:1) with unresectable HCC, prior not treated with systemic therapies
- Results: @median follow-up of 15.6mos., 34% reduction in OS; m-OS (19.2 vs 13.4mos.); mPFS (6.9 vs 4.3mos.). In Chinese population, m-OS (24.0 vs 11.4mos.)
- Tecentriq + Avastin is an approved therapy across the globe, including in the US, China, Japan and the EU, for people with unresectable HCC and is recommended in many clinical practice guidelines globally
Click here to read full press release/ article | Ref: Roche | Image: BioSpace
The post Roche Reports Updated OS Data of Tecentriq + Avastin in P-III IMbrave150 Study for Unresectable HCC first appeared on PharmaShots.